Virax Biolabs Group (Virax Biolabs Group) FCF Margin % : -5,410.39% (As of Sep. 2023)

View and export this data going back to 2022. Start your Free Trial

What is Virax Biolabs Group FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Virax Biolabs Group's Free Cash Flow for the six months ended in Sep. 2023 was $-4.17 Mil. Virax Biolabs Group's Revenue for the six months ended in Sep. 2023 was $0.08 Mil. Therefore, Virax Biolabs Group's FCF Margin % for the quarter that ended in Sep. 2023 was -5,410.39%.

As of today, Virax Biolabs Group's current FCF Yield % is -320.05%.

The historical rank and industry rank for Virax Biolabs Group's FCF Margin % or its related term are showing as below:

VRAX' s FCF Margin % Range Over the Past 10 Years
Min: -48422.22 Med: -745 Max: -475.81
Current: -7561.25

During the past 4 years, the highest FCF Margin % of Virax Biolabs Group was -475.81%. The lowest was -48422.22%. And the median was -745.00%.

VRAX's FCF Margin % is ranked worse than
90% of 1040 companies
in the Biotechnology industry
Industry Median: -141.08 vs VRAX: -7561.25

Virax Biolabs Group FCF Margin % Historical Data

The historical data trend for Virax Biolabs Group's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Virax Biolabs Group FCF Margin % Chart

Virax Biolabs Group Annual Data

Trend

Mar20

Mar21

Mar22

Mar23

FCF Margin %

-745.00

-475.81

-48,422.22

Virax Biolabs Group Semi-Annual Data
	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
FCF Margin %	Get a 7-Day Free Trial			-	-	-38,266.67	-62,766.67	-5,410.39

Competitive Comparison of Virax Biolabs Group's FCF Margin %

For the Biotechnology subindustry, Virax Biolabs Group's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Virax Biolabs Group's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Virax Biolabs Group's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Virax Biolabs Group's FCF Margin % falls into.

Virax Biolabs Group FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Virax Biolabs Group's FCF Margin for the fiscal year that ended in Mar. 2023 is calculated as

FCF Margin	=	Free Cash Flow (A: Mar. 2023 )	/	Revenue (A: Mar. 2023 )
	=	-4.358	/	0.009
	=	-48,422.22 %

Virax Biolabs Group's FCF Margin for the quarter that ended in Sep. 2023 is calculated as

FCF Margin	=	Free Cash Flow (Q: Sep. 2023 )	/	Revenue (Q: Sep. 2023 )
	=	-4.166	/	0.077
	=	-5,410.39 %

Virax Biolabs Group FCF Margin % Related Terms

Thank you for viewing the detailed overview of Virax Biolabs Group's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.

Virax Biolabs Group (Virax Biolabs Group) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Virax Biolabs Group Ltd (NAS:VRAX) » Definitions » FCF Margin %

Comparable Companies

Traded in Other Exchanges

N/A

Address

20 North Audley Street, London, GBR, W1K 6LX

Website

https://www.viraxbiolabs.com

Virax Biolabs Group Ltd is a innovative biotechnology company focused on the prevention, detection, diagnosis and risk management of viral diseases that also engages in distribution of diagnostics test kits of various viral threats. It is developing a proprietary T-Cell Test technology with the intention of providing an immunology profiling platform that assesses each individual's immune risk profile against major global viral threats. T-Cell testing is particularly effective in the diagnosis and therapeutics of COVID-19 as well as other threats including Hepatitis B, Malaria, Herpes and Human Papillomavirus.